We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

3 hedge funds and large institutions have $3.53M invested in Tonix Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

290% more capital invested

Capital invested by funds: $906K → $3.53M (+$2.62M)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

50% more funds holding

Funds holding: 2 → 3 (+1)

0% less ownership

Funds ownership: 0% → 0% (-0%)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.21M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$606K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$606K
2
Jane Street
Jane Street
New York
-$38K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13K
4
ARTA
A.R.T. Advisors
New York
-$10K
5
CAN
Cetera Advisor Networks
California
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.24M +$1.21M +2 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$602K +$606K +1 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$433K – – –
Squarepoint
4
Squarepoint
New York
$262K – – –
BCM
5
Bridgeway Capital Management
Texas
$222K – – –
Northern Trust
6
Northern Trust
Illinois
$211K – – –
VF
7
Virtu Financial
New York
$79K – – –
Charles Schwab
8
Charles Schwab
California
$77K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$67K -$606K -1 Closed
OPS
10
Orion Portfolio Solutions
Nebraska
$67K – – –
GCP
11
GSA Capital Partners
United Kingdom
$66K – – –
JP Morgan Chase
12
JP Morgan Chase
New York
$33K – – –
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
$24K – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$23K – – –
EH
15
Equitable Holdings
New York
$17K – – –
SGI
16
Summit Global Investments
Utah
$17K – – –
Victory Capital Management
17
Victory Capital Management
Texas
$17K – – –
TSS
18
Two Sigma Securities
New York
$16K – – –
SFS
19
Sowell Financial Services
Arkansas
$13K – – –
IA
20
IFP Advisors
Florida
$10K – – –
FDCDDQ
21
Federation des caisses Desjardins du Quebec
Quebec, Canada
$9.24K – – –
BCI
22
Brinker Capital Investments
Pennsylvania
$9K – – –
FA
23
FCG Advisors
New Jersey
$9K – – –
GWM
24
Geneos Wealth Management
Colorado
$3K – – –
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$2K – – –
1
2

TNXP Hedge Fund Activity: Q3 2020 in Review

3 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2020, worth a combined $3.53M — up 290% from $906K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new TNXP positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $1.21M. The largest seller was Citadel Advisors, exiting entirely with an estimated $606K sold.

  • 3 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2020, up from 2 in Q2 2020.
  • Funds reported $3.53M of Tonix Pharmaceuticals stock for Q3 2020, up 290% quarter-over-quarter.
  • 2 funds opened new Tonix Pharmaceuticals positions in Q3 2020 and 1 closed out, a net change of +1 holder.
  • The largest Tonix Pharmaceuticals buyer in Q3 2020 was BlackRock, an estimated $1.21M added.
  • The largest Tonix Pharmaceuticals seller in Q3 2020 was Citadel Advisors, an estimated $606K sold.

Based on aggregated 13F filings for Q3 2020.